GlassScriptPhysician profile
Kiarash Zarbalian
NPI 1467587063
$2,861.35
in general payments reported to CMS, 2019-2025
18 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $273 · 2021: $311 · 2022: $674 · 2023: $512 · 2024: $361 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $356.37 | 2022-2025 | Minimed 780g |
| Horizon Therapeutics Plc | $332.90 | 2022-2023 | Tepezza |
| Dexcom, INC. | $251.73 | 2019-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Astrazeneca Pharmaceuticals LP | $244.47 | 2020-2021 | |
| Insulet Corporation | $221.88 | 2021-2023 | Omnipod |
| Tandem Diabetes Care, INC. | $197.77 | 2020-2022 | |
| Novo Nordisk INC | $191.36 | 2021-2022 | |
| Corcept Therapeutics | $161.42 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $137.88 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Beta Bionics, INC. | $118.89 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $115.79 | 2023 | |
| Valeritas, INC. | $110.66 | 2019 | |
| Lilly USA, LLC | $101.72 | 2022 | |
| Medtronic Minimed, INC. | $93.92 | 2019 | |
| Cequr Corporation | $66.88 | 2023 | Cequr Simplicity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $54.56 | 2022 | |
| Zealand Pharma US, INC. | $53.61 | 2020 | |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiarash Zarbalian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.